MERZ-AESTHETICS
20.10.2020 12:38:06 CEST | Business Wire | Press release
Merz Aesthetics, a global leader in medical aesthetics, today announced that Radiesse® is celebrating ten million syringes shipped worldwide over almost twenty years. Radiesse® is a unique calcium hydroxylapatite (CaHA) injectable filler1 used for volumization, lifting and contouring, as well as skin rejuvenation by stimulating natural collagenogenesis.2,3 The product portfolio includes Radiesse® and Radiesse® Lidocaine delivering effective and natural-looking cosmetic results, distinguished by its established safety profile4 and high patient satisfaction.5
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201020005619/en/
“As we reflect on this milestone, we are proud of the fact that, Radiesse has proven to provide aesthetic practitioners with a unique treatment that they can administer confidently, while supporting their patients’ desired impact,” said Kristel Hectors, Head of Marketing EMEA, Merz Aesthetics. “With almost twenty years of scientific evidence and clinical experience, Radiesse is such a unique product and full of opportunities and possibilities. As we are looking ahead, we are excited for what’s to come over the next years for Radiesse.”
The milestone campaign launching under the tagline “The Power Used By Millions” reinforces the uniqueness of the product and its working mechanism. Informing health care professionals and educating patients on the uniqueness of Radiesse® , on its working mechanism and efficacy.
“Radiesse is my number one go to product because of its versatility. Radiesse plus for contouring, lifting, ligaments and volumizing. Classic Radiesse for classic indications like folds and of course hyperdiluted Radiesse for skin quality improvement,” said Jani van Loghem, MD Cosmetisch arts KNMG. “It is a biostimulatory product going beyond a hyaluronic acid: the collagen will be giving the patient the final result and it is a really nice message to the patient! That’s why I choose Radiesse.”
About Radiesse®
/Radiesse®
(+) Lidocaine
Radiesse®
is an injectable dermal filler that provides immediate volume and correction and continues to work by stimulating the body’s own natural collagen production. In addition, Radiesse activated the self-renewing potential within the skin to make the skin firm, elastic and strong. Radiesse can be tailored to individual requirements and skin condition.1,6-10
Radiesse® (+) Lidocaine injectable implant is an opaque, dermal filler that contains a small quantity of local anesthetic (lidocaine). In Europe, Radiesse® (+) Lidocaine is indicated for plastic / reconstructive procedures, including deep dermal and subdermal soft tissue augmentation of the facial area and for restoration and correction of facial volume loss. The presence of lidocaine is intended to reduce patient pain and to enhance comfort during treatment.1,6-10
Radiesse® / Radiesse® (+) Lidocaine is valued by doctors and patients around the world for its tolerability and safety profile. Radiesse received the CE mark for aesthetic use in Europe in 2004, with U.S. FDA approval following in 2006. In that time, Radiesse has been considered a leading minimally-invasive aesthetic treatment trusted by healthcare providers around the world. The product has been available on the market for more than fifteen years, with now 10 million syringes shipped worldwide and a clinically proven safety profile supported by more than 200 clinical studies and peer-reviewed publications.1,6-10
Radiesse is available in more than 70 countries worldwide.
About Merz Aesthetics
At Merz Aesthetics, we are a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves. Clinically proven, our product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with the highest standards of safety and efficacy. We are known for building unique connections with customers who feel like family. Our global headquarters is in Raleigh, N.C., USA, with locations in 32 countries worldwide. Merz Aesthetics is part of Merz Group, a family owned company founded in 1908 and based in Frankfurt, Germany. Learn more at merzaesthetics.com.
Copyright © 2020 Merz Pharmaceuticals GmbH. All rights reserved. MERZ, MERZ AESTHETICS and the MERZ logo are registered trademarks of Merz Pharma GmbH & Co. KGaA. Radiesse® is a registered trademark of Merz North America, Inc.
1 RADIESSE Instructions for Use Nov. 2017. RADIESSE® Lidocaine Instructions for Use Jun.2018.
2 Berlin AL, et al. Dermatol Surg. 2008;34(suppl 1):S64-S67.
3 Moers-Carpi M, et al. Dermatol Surg. 2007;33(suppl 2):S144-S151.
4 Van Loghem JV, et al. J Clin Aesthet Dermatol. 2015:8(1)38-49.
5 Juhász MLW, Marmur ES, Dermatol Surg. 2018;44(8)1084-93.
6 Yutskovskaya Y, et al. J Drugs Dermatol. 2014;13(9):1047-52.
7 Yutskovskaya YA, Kogan EA. J Drugs Dermatol. 2017;16(1):68-74.
8 Schachter D, et al. J Drugs Dermatol. 2016 Aug 1; 15(8): 1005-10.
9 Sundaram H, et al. Dermatol Surg. 2010;36 (suppl 3):1859-1865.
10 Schachter Science Brief: Pain Control using the Injectable Dermal Filler Radiesse (+) for the correction of Nasolabial folds. Daniel Schachter, Vince Bertucci, Nowell Solish. POSTER PRESENTATION at 13th Anti-Aging Medicine World Congress (2015), Monaco, Monte Carlo.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201020005619/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom